Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with congenital hyperinsulinism~Exclusion Criteria:~* Acute medical illness~* History of other systemic chronic disease such as cardiac failure, renal insufficiency, hepatic insufficiency, chronic obstructive pulmonary disease, anemia, or uncontrolled hypertension~* Pregnancy~* Diabetes mellitus~* Use of medications that affect glucose metabolism, such as glucocorticoids, beta agonists, diazoxide and octreotide.~* Subjects will be eligible to participate 48 hrs after the last dose of octreotide and 72 hrs after last dose of diazoxide

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Exendin-(9-39) first, the Vehicle (Type: EXPERIMENTAL): Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
- Vehicle first, then Exendin-(9-39) (Type: PLACEBO_COMPARATOR): Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).